

MuPrime™ Tumor Homografts


Immunocompetent models carrying clinically-relevant oncogenic mutations

MuPrime models are homografts of spontaneous or carcinogen induced GEMM tumors grafted in immunocompetent syngeneic hosts. Developed from virtually any GEMM, tumor homografts are broadening the number and molecular pathology of syngeneic models for preclinical I/O research.



MuPrime tumor homografts are never passaged *in vitro* or *ex vivo*. As a result, the original tumor histopathology, molecular pathology, and key oncogenic driver mutations are preserved.

The **MuPrime** platform offers:

- Unique models, encompassing disease-specific mutations relevant to human cancers.
- The predictive power of GEMM combined with operational simplicity required for *in vivo* pharmacology studies.
- A fully competent mouse immune system.
- Well-characterized models with histopathology, immune checkpoint and SoC benchmarking, and immune profiling data available via our online database **MuBase**®.
- Scalability that enables large-scale screening.



Kras (G12D)/Trp53 null/Pdx1-cre (KPC) tumor homograft model for the evaluation of novel pancreatic ductal adenocarcinoma (PDAC) treatments



Contact Sales

US: +1.855.827.6968
UK: +44 (0)870 166 6234
busdev@crownbio.com



Schedule Scientific Consultation

Request a consultation to discuss your project.
consultation@crownbio.com



Explore Scientific Data

Log into **MuBase** to review murine I/O model data.
mubase.crownbio.com